Antabio completes Phase 1 clinical study of MEM-ANT3310 for severe hospital infections
Antabio completed Phase 1 trial for MEM-ANT3310, a broad-spectrum antibacterial combination designed to combat antimicrobial resistance in severe hospital infections. The trial showed good tolerability and no serious adverse events, supporting further patient studies.
Reference News
Antabio completes Phase 1 clinical study of MEM-ANT3310 for severe hospital infections
Antabio completed Phase 1 trial for MEM-ANT3310, a broad-spectrum antibacterial combination designed to combat antimicrobial resistance in severe hospital infections. The trial showed good tolerability and no serious adverse events, supporting further patient studies.